This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	§	
Mar Tormo	§	
Ana M. Tari	§	
Gabriel Lopez-Berestein	§	
	§	Group Art Unit: 1805
Serial No. 08/726,211	§	-
	§	Examiner: R. Schwartzman
Filed: October 4, 1996	§	
	§	Atty. Dkt.: UTXC:504/COD
For: INHIBITION OF BCL-2 PROTEIN	§	•
EXPRESSION BY LIPOSOMAL	§	
ANTISENSE	§	
OLIGODEOXYNUCLEOTIDES	§	

DECLARATION OF GABRIEL LOPEZ-BERESTEIN AND ANA M. TARI UNDER 37 C.F.R. §1.131

WE, DR. GABRIEL LOPEZ-BERESTEIN AND DR. ANA M. TARI DECLARE AS FOLLOWS:

- 1. We, along with Dr. Mar Tormo, are co-inventors of the subject matter of the captioned patent application USSN 08/726,211.
- 2. It is our understanding that the Examiner in charge of the captioned application has rejected claims 1, 2, 5 and 6 as being anticipated by the abstract of Tormo *et al.* abstract #1190, *Proceedings of the American Association for Cancer Research*, vol. 37 pg 173, March 1996, and has rejected claims 1 and 2 as anticipated by the abstract of Almazan et al. abstract #2407, *Proceedings of the American Association for Cancer Research*, vol. 37 pg 353, March 1996.

- 3. Our invention was made and tested in this country prior to March 1996 and thus prior to the publication of the cited abstracts.
- 4. The fact that our invention was made and tested in this country prior to March of 1996 is evidenced by studies set forth in the attached notebook pages 280-288 of the laboratory notebook of Mar Tormo. Among other things, this notebook sets forth the following studies which exemplify the practice of our invention:
- a) measurement of expression of Bcl-2 in Johnson, Daudi, Raji and Jurkat cells (p.
 280);
- b) a test of growth inhibition of the cell lines with liposomal AS (antisense), C (control) and B₂ oligonucleotides (p. 280-281);
- c) graphs depicting apoptotic index of cells and cell density after treatment with control and antisense oligonucleotides (p. 282);
- d) a repeat of the study of measurement of expression of Bcl-2 in Johnson, Daudi, Raji and Jurkat cells (p. 282-283);
- e) growth inhibition studies of Johnson, Daudi, Raji and Jurkat cells in the presence of antisense and control liposomal oligonucleotides.

Each of items a) through e) as represented in the attached notebook were carried out in this country prior to March 1, 1996.

5. All statements made in this Declaration of my own knowledge are true and all statements made in this Declaration on information and belief are believed to be true, and these statements are made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both under 18 U.S.C. §1001 and may jeopardize the validity of this application or any patent issuing thereon.


-	1-6,98	
Date	U	


Gabriel Lopez-Berestein

1-7-98


Date

Ana M. Tari





1.3



			AS	·.		C.	٠.		9) ·	1) 14 1	
	2	_	98%	-		100	<u> </u>	eter (104		C'h	nàh		
	3		96/	14	بلاام	98%	/		-97	/		. •	امواف کرد انف	
	4		85/		المثارة المثالة	92/		ا المائدة المائدة المائدة المائدة المائدة	499	1			***	· Naga
	611	1	99 /			-35)	/		-9i'/					É
7	1		0 /			0/			87/		***	· ·		
iability	8		0:/	and the last	i de la companya de l	0/.		همها المحاصر في ا مهامات ما ادار مود ود	72	/ 1				
	(4)	Da	uol		-	-	- X			4				
												1		
	4	2	<u>3</u>	-0.123	-5	_G.	1.7	8	.ø	Blo	чК			
	18	0.533	0.351	0.225	-0.202 -0.215	-0.219 -0.221	-0.222 -0.217	-0.219 -0.220	-0.481 0.498	-0.227 -0.229	in Specific region (Specific Control of Cont			
	,	0.489	0.463	0.337	0.076	-0.203	-0.213	-0.222	0.516					
		0.503	0.451	0.281	0.170	-0.148	-0.220	-0.215	0.510	deples time capturary a	a Çabi esagayı i			4
	82	0.514	0.463 0.461	0.419	0.387	0.238	-0.099	-0.103	0.458	Tanakaran	•	-		
			0.401	0.470	0.388	0.209	-0.021	-0.144	0.520		,		-:	_
			*****	AS		(B ₂	,*, ,		. 1 '1 4	-	
					 ,			. · <u>-</u>		·.	(80h	ah lit	5	4
	2	٠		9 7 /.		. 8			89,				1	7
				62% m:/			°0%. 54%.	· ·	787					1
·		•		39/. 0%			17. 17.		687				-	╬
	6			0/.). }.	•	46		:			┪
	7		• •	o'/.			./.	-	0/	,]
	8	<u> </u>	* * ••	0/.	• • •	C	7.		0,	/.				+
	,				*******	2	• =							_
														+
					***,			<u> </u>						十

- 15 - 10 11 WED ORD - 15 6		
1) To test it there are 60-2	inhi 58	2
with AS DORC: 2345.	and Figure	
of AS and Colifo		;
(2) there the oligo like alwa	m air	
sourcate for 12' (4'-4'-4')	D> *	
aite measurament of the	A DOME!	H
		and James
F-ANN CUPTAKE Menu File: C370.TBL 1/3/96		AND COMPANY
r de la	14.0	;
Run time Data Ch tensity, In Sensitive O Hours 7 Mins 48 Secs 131.7K l. 5kHz 138 255 Gaussian Analysis (Vesicl Distribution Analysis		
Mean Dia Std Dev Chi Sq Ba'eak d; Peak 2 Peak		
VOL: 152.3 nm 112.7 nm 297.42 12.5 % 35.5 192 74.0 % 5.4 % 54.1 % 40.	1750	
INT: 133.2 nm 98.5 nm 297.42 12.7 : 36.1 176 74.0 % 1.3 % 35.7 % 63.	.8 Residual 1 × 51.909	-
NUM: 24.8 nm 18.3 nm 297.42 29.1 169.6	_	
	4	
F-ANN UPTAKE / Menu File: C370. TBL 1/3/96		
Run time Data Chntensity & Sensitive 24 Secs _ 37.9K .4kHz 10 . 255	ity	
Gaussian Analysis (Vesic Distribution Analysis Chi Sq BPeak 1 Peak 2 Peak	1815	
VOL:76.0.nm 51.3 nm 4.44 26.0 ♯ 80.7 67.5 ⅙ 30.1 ⅙ 69.9 ⅙	- Fit Error - 15.788	
INT: 87.2 nm 58.8 nm 4.44 27.9 81.7 67.5 % 14.6 % 85.4 %	- Residual 47.565	
NUM: 18.3 nm 12.3 nm 4.44 21.4 63.4 67.5 % 92.1 % 7.9 %		r
(4) Add to the Cells (Johnson)	s als	
- Plated in a 24 well plate at.	the 100 mo	
'Colls/well, I w/ w each well		_
ETI-L-		-
(5) + harrate for 3 days.		

			· • • • • • • • • • • • • • • • • • • •	الدم لم			٠١ . ح	લ્ટ્રી ⁸⁷	
	2	lives	CILL SE	*	12 0.	- my	191 21	<u>(QI) .</u>	\dashv
		distr	100		vem vem	807 POL		到	<u> </u>
ich bition	1.12 Noure 3. 272	Pajo	and "	it-lcot	colle	vavid	เมื่อม		
and 7 m		111 . U	MOUNT D	1 note	<u>""</u>	calu		à	
	and the second	ive Fit: , Linear	And the C				51 556 1 60		
o and	Ec	uation: $y = A +$	B X			Corr. C	its: ug/ul	WE.	
			00769 B = 0.28		Marinary Marinary			A COMMENT	
to Donnie	PLATE BLAN	IK 🌃	W.C.	Well Al2	OD	Mean 0.053	Std Dev	CV	 }.
	*********	***************************************				1177	1		• •
	STD01	Value 0.000	ug/ul	Well Al	OD 0.017	0.012	Std Dev 0.005	CV 38.19	
	4			B1 C1	0.011	سأب المسائد المسا			-∦,
ity	STD03	0.500	ug/ul	A3 B3	0.186 0.156	0.144	0.050	34.57	
3		And the second s	and the property of the second	සි	0.089	1	in the second		
.0 Fit Error 5 % 5.813	STD04	0.750	ug/ul	A4 B4	0.398 0.182	0.224	0.157	70.21	
.8 Residual		and the second of the second o	المستحديد والمحاجدة	C4	0.092				
	STD06	1.500	ug/ul	A6 B6 C6	0.588 0.389 0.342	0.440	0.131	29.70	
		· · · · · · · · · · · · · · · · · · ·	an american	<u> </u>	. U.342	. N	e e e e e e e e e e e e e e e e e e e e	0.00-	
	UNKNOWNS	Mean 1.940	Std Dev 0.264 1	CV Well 3.61 E3	Value 1.754	OD 0.058	Dil.Fa 10.00	ctor	_
ity S				F3 G3	1.824 2.243	0.060 0.072			十
	JOHNS	1.754	0.160 9	.108 E1	1.929	0.063	10.00		十
3				F1 G1	1.720	0.054			
- Fit Error 15.788	JURK	1.603	0.053	.322 E2 F2	1.615 1.650	0.054	10.00	***	
- Residual				G2	1.545	0.052		·	
=	RAJI	2.836	0.126 4	.434 E4 F4	2.731	0.086	10.00		
			(446)	G4 -	2.975	0.093	ı.j		
ع مال	thou		(Z 11 - D)	uteol	11 m	July .	1100	•	·
the 100,000	L'UR	Sample	Jan June	(1) 3x 8	<u>B: 1</u>	26. 02	W.		
		714	- J			115	<u> </u>		
	4	α : .	म स्वतं 0	97	<u>)</u> 15;	40	NC	 	
<u> </u>	2 12 2 15	Daud	1). 4 + /i		: : :36 : : 44	ul		_
	3 '	JUHCO	<u> </u>) 802 420	· · · ·	1144			\dashv
1	7	My		· 7/U		<u>W</u> S_	jue.	· <u>-</u>	-
		-, , <u> </u>							

